Boston Scientific Corporation (NYSE:BSX) delivered stronger-than-expected results for the fourth quarter of 2025 on Wednesday, with both earnings and revenue coming in ahead of Wall Street estimates, although the stock edged lower in premarket trading.
Shares of the medical device maker were down 0.47% ahead of the open following the earnings release.
Adjusted earnings per share for the quarter reached $0.80, beating the consensus forecast of $0.78. Revenue totaled $5.29 billion, marginally above analysts’ expectations of $5.28 billion and up 15.9% on a reported basis from the same period a year earlier. Organic revenue growth was 12.7%, landing at the upper end of the company’s guidance range of 11% to 13%.
“2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals,” said Mike Mahoney, chairman and chief executive officer. “As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future.”
Growth was led by the Cardiovascular segment, which posted an 18.2% increase in reported revenue, while the MedSurg division recorded revenue growth of 11.7%. From a geographic perspective, sales in the United States rose 17.0%, and revenue from emerging markets increased 15.4%.
For the full year 2025, Boston Scientific reported adjusted earnings per share of $3.06 on revenue of $20.07 billion, representing a 19.9% increase compared with 2024.
Looking ahead, the company issued guidance for 2026 that calls for organic revenue growth of 10% to 11% and adjusted earnings per share in the range of $3.43 to $3.49, broadly in line with analyst expectations of $3.47.
Boston Scientific also highlighted recent strategic moves, announcing agreements to acquire Penumbra, Inc. and Valencia Technologies Corporation as part of its ongoing effort to expand and strengthen its medical device portfolio.